A recent study indicated no evident VTE risk in patients with eczema, despite FDA black box warnings for the drug class.
Tim Smith
Advertisement
Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at [email protected].
Articles by Tim Smith
Advertisement
Advertisement
Advertisement
Trending on HCPLive
1
OMA 2026 Recap: Pediatrics, Retention, and Lifestyle Changes in Obesity
2
OMA 2026 Recap: GLP-1s in Conditions Beyond Obesity
3
A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease
4
Choosing Among Approved JAK Inhibitors: Baricitinib, Ritlecitinib, and Deuruxolitinib
5